When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
Circulating tumor DNA and its correlation with survival in hormone receptor positive HER2-negative stages I-III breast cancer: A systematic review. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
US FDA approves expanded use of Agilent’s PD-L1 IHC 22C3 pharmDx on Dako Omnis in ESCC, TNBC, and gastric or gastroesophageal junction adenocarcinoma: Santa Clara, California Fr ...
ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months. Surgical outcomes in patients with non-small cell lung cancer receiving neoadjuvant ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results